Hohimer Wealth Management LLC Acquires 12,583 Shares of United Therapeutics Corporation $UTHR

Hohimer Wealth Management LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, HoldingsChannel reports. The institutional investor acquired 12,583 shares of the biotechnology company’s stock, valued at approximately $6,819,000.

Other institutional investors have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. grew its position in shares of United Therapeutics by 53.1% during the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 14,282 shares of the biotechnology company’s stock valued at $7,739,000 after buying an additional 4,954 shares during the last quarter. Candriam S.C.A. lifted its holdings in United Therapeutics by 2.7% in the third quarter. Candriam S.C.A. now owns 55,109 shares of the biotechnology company’s stock worth $29,972,000 after acquiring an additional 1,425 shares during the last quarter. Ethic Inc. lifted its holdings in United Therapeutics by 60.0% in the third quarter. Ethic Inc. now owns 2,463 shares of the biotechnology company’s stock worth $1,335,000 after acquiring an additional 924 shares during the last quarter. StoneX Group Inc. bought a new position in United Therapeutics in the third quarter worth about $400,000. Finally, Parallel Advisors LLC boosted its stake in United Therapeutics by 2.1% in the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock valued at $625,000 after acquiring an additional 24 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $562.02 on Monday. United Therapeutics Corporation has a fifty-two week low of $444.04 and a fifty-two week high of $614.23. The firm’s 50-day simple moving average is $533.99 and its 200 day simple moving average is $533.42. The stock has a market cap of $23.94 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 3.78 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $7.16 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 24.77 EPS for the current fiscal year.

United Therapeutics announced that its Board of Directors has authorized a stock repurchase plan on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 1,960 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $597.76, for a total transaction of $1,171,609.60. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $193,939,047.68. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $598.67, for a total value of $4,968,961.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $27,043,121.24. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 401,528 shares of company stock worth $213,440,124 in the last 90 days. 8.60% of the stock is owned by company insiders.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

Analyst Ratings Changes

Several research firms have recently commented on UTHR. Leerink Partners upped their target price on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Raymond James Financial set a $720.00 price target on United Therapeutics in a research report on Wednesday. Wells Fargo & Company raised their price target on United Therapeutics from $700.00 to $703.00 and gave the stock an “overweight” rating in a report on Thursday. TD Cowen boosted their price objective on United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada boosted their price objective on United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research report on Thursday. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $676.40.

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.